New data highlight immune response to COVID-19 vaccines in individuals with relapsing forms of multiple sclerosis treated with Zeposia.- BMS
Bristol Myers Squibb announced new data on COVID-19 vaccine responses in participants treated with Zeposia (ozanimod) from the ongoing Phase III DAYBREAK open-label extension (OLE) study in relapsing multiple sclerosis.
For participants who showed no evidence of recent COVID-19 infection, results showed seroconversion occurred in 100% (80/80) and 62% (18/29) of fully vaccinated mRNA and non-mRNA vaccine recipients, respectively.
These data are to be presented as late-breaking research (Presentation #OPR-162) on June 28, 2022 (8:45-9:00 CEST) at the European Academy of Neurology (EAN) Congress in Vienna, Austria.
This research was conducted from January 2020 to October 2021, and higher antibody levels were observed at all tested timepoints from four weeks to greater than 12 weeks in mRNA vaccine recipients who completed the two-dose regimen (grand mean 512.6 U/mL, range: 1.3-4572) versus those with one dose (grand mean 39.3 U/mL, range: 0.4-368.5) indicating that patients on Zeposia develop an adequate primary response and may receive a potential benefit from booster doses.
“This study shows that all participants who received Zeposia as a treatment for multiple sclerosis were able to develop an immune response following mRNA vaccinations against COVID-19 infection,” said Bruce Cree, MD, PhD, MAS, study investigator and professor of Clinical Neurology, University of California San Francisco (UCSF) Weill Institute for Neurosciences and clinical research director, UCSF MS Center. “Patients treated with Zeposia are much more likely to develop antibody responses to RNA vaccines compared to non-RNA vaccines. This observation may be helpful for physicians as they seek to optimize care for patients in the face of the ongoing COVID-19 pandemic.”
In a separate analysis of treatment-emergent COVID-19 events occurring from November 1, 2019 to May 10, 2021, results showed that the benefit:risk profile of Zeposia remains unchanged with most COVID-19 cases being non-serious, with the majority resolving without treatment interruption.
“We are committed to partnering with the research and medical communities to understand how our medicines should best be used in the context of the evolving COVID-19 pandemic,” said Jonathan Sadeh, MD, MSc, senior vice president of Immunology and Fibrosis Development, Bristol Myers Squibb. “While more research is required, these data further confirm Zeposia’s consistent safety profile and demonstrate that individuals receiving Zeposia for multiple sclerosis mount a measurable antibody response to COVID-19 vaccination.”
Bristol Myers Squibb-sponsored abstracts that will be presented at the EAN Congress 2022 are listed below. Complete abstracts can be accessed online here:. Zeposia Presentations : i."Serologic response to SARS-CoV-2 vaccines in DAYBREAK participants with relapsing multiple sclerosis receiving ozanimod."Author: Bruce Cree. Presentation number: OPR-162. ii."Positive association between baseline brain volume and long-term cognition in patients with relapsing multiple sclerosis". Author: John DeLucae Poster number: EPO-127. iii."Analysis of multiple sclerosis relapse following discontinuation of ozanimod in DAYBREAK".Author: Ralf GoldePoster number: EPO-131. iv."Efficacy of ozanimod in disease-modifying treatment naive vs experienced patients with relapsing multiple sclerosis" .Author: Hans-Peter Hartung.ePoster number: EPR-050 v."Long-term outcomes with ozanimod in the DAYBREAK extension trial by number of multiple sclerosis relapses during the Phase III trials"/Author: Patrick Vermersch.ePoster number: EPR-160.
Related news and insights
Palisade Bio, Inc. announced the first patient has been dosed in its Phase III study evaluating LB 1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery.
bluebird bio, Inc. announced the FDA has approved Zynteglo (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions.
Edwards Lifesciences Corporation announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the treatment of mitral and tricuspid regurgitation (MR and TR).